Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 2/20 | 0.39 |
| ▸ | MC3R | P41968 | 2/20 | 0.39 |
| ▸ | MC1R | Q01726 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 16/20 | 0.39 |
| ▸ | CA2 | P00918 | 16/20 | 0.39 |
| ▸ | CA4 | P22748 | 16/20 | 0.39 |
| ▸ | CA9 | Q16790 | 16/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3494442 | 0.95 | CA1 (0.40) | MC4RMC3RMC1RCA1CA2 | |
| SCHEMBL3493485 | 0.95 | CA1 (0.40) | MC4RMC3RMC1RCA1CA2 | |
| SCHEMBL3495613 | 0.95 | CA1 (0.40) | MC4RMC3RMC1RCA1CA2 | |
| SCHEMBL4281780 | 0.90 | CA1 (0.42) | MC4RMC3RMC1RCA1CA2 | |
| SCHEMBL8230034 | 0.89 | ABHD6 (0.44) | CA1CA2CA4CA9 | |
| SCHEMBL3493838 | 0.86 | CA1 (0.41) | MC4RMC3RMC1RCA1CA2 | |
| SCHEMBL3493179 | 0.85 | MC4R (0.39) | MC4RMC3RMC1RCA1CA2 | |
| SCHEMBL3494062 | 0.85 | CA1 (0.48) | MC4RMC3RMC1RCA1CA2 | |
| SCHEMBL8238449 | 0.85 | ABHD6 (0.46) | CA1CA2CA4CA9 | |
| SCHEMBL8238579 | 0.85 | ABHD6 (0.46) | CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-1984355-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | Takeda Pharmaceutical Company Limited (JP) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007094513-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | MC4R 1120/4885MC3R 334/4885MC1R 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.